Shifting the Dosing Paradigm
By April 22, 2026, the 'MARITIME' trial results for MariTide confirm extreme durability. Monthly or quarterly dosing solves the #1 hurdle in 2026 metabolic care: long-term adherence.
Strategic Data Expansion 2026.4
The 'Legacy Effect'
Benefits persist for months after the last dose. [Image showing the pharmacokinetic curve of MariTide] LSI keywords like 'antibody-peptide conjugate' are the focal point for endocrinology.
Injection Burden Reduction
Injections Per Year
$$N = rac{8760 ext{ hours}}{I_d}$$
Strategic Advice: If weekly rituals are too burdensome, MariTide is the 2026 therapy to watch.